TransCode Therapeutics (NASDAQ:RNAZ) Releases Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ) released its quarterly earnings data on Friday. The company reported ($5.82) EPS for the quarter, FiscalAI reports.

TransCode Therapeutics Stock Performance

RNAZ stock traded up $0.82 on Friday, reaching $9.24. The company’s stock had a trading volume of 6,572 shares, compared to its average volume of 20,181. The business has a fifty day simple moving average of $11.56 and a two-hundred day simple moving average of $10.08. TransCode Therapeutics has a 12-month low of $6.15 and a 12-month high of $468.44. The firm has a market cap of $7.67 million, a PE ratio of -0.05 and a beta of 1.51.

Analysts Set New Price Targets

A number of equities analysts have commented on RNAZ shares. Wall Street Zen cut TransCode Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 30th. Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, TransCode Therapeutics has an average rating of “Hold” and a consensus price target of $280.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Warberg Asset Management LLC bought a new stake in shares of TransCode Therapeutics Inc. (NASDAQ:RNAZ) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 50,000 shares of the company’s stock, valued at approximately $25,000. Warberg Asset Management LLC owned approximately 0.21% of TransCode Therapeutics at the end of the most recent quarter.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.